Insightec Announces Registration Approval Of Exablate Neuro By Singapore Health Sciences Authority
PR90423
HAIFA, Israel and MIAMI, July 5, 2021 /PRNewswire=KYODO JBN/ --
Positive momentum continues to bring Focused Ultrasound to global patients
living with Essential Tremor and Tremor-dominant Parkinson's Disease
Insightec(R) [ http://www.insightec.com/ ], a global healthcare company focused
on creating the next generation of patient care, announced approval of the
Exablate(R) Neuro platform by the Health Sciences Authority (HSA) in Singapore.
The Exablate Neuro (Exablate 4000) platform uses Focused Ultrasound to ablate a
target deep in the brain. The unilateral treatment is suitable for patients
with Essential Tremor (age 22 or older) or Tremor-dominant Parkinson's Disease
(age 30 or older) who have not responded to medications.
"The value of Focused Ultrasound for medical centers treating movement
disorders is greatly improved patient care," said Maurice R. Ferré MD,
Insightec CEO and Chairman of the Board of Directors. "Our technology enables
patients to go from a life dominated by tremor to the potential for a calm,
steady hand."
There are 81 leading medical centers globally that have established Focused
Ultrasound programs with Exablate Neuro. Insightec is working with Transmedic [
http://www.transmedicgroup.com/ ]Group, a leading distributor of advanced
medical technology in Southeast Asia, to advance adoption of the Exablate Neuro
in the Singapore market.
"We are excited to bring this transformational technology to medical centers in
Singapore," commented Teo Kee Meng, Transmedic Managing Director. "More
importantly, patients will now have the option to choose a treatment that is
outpatient and incisionless."
About Insightec
Insightec is a global healthcare company creating the next generation of
patient care by realizing the therapeutic power of acoustic energy. The
company's Exablate(R) Neuro platform focuses sound waves, safely guided by MRI,
to provide tremor treatment to patients with Essential Tremor and
Tremor-dominant Parkinson's Disease. Research for future applications in the
neuroscience space is underway in partnership with leading academic and medical
institutions. Insightec is headquartered in Haifa, Israel, and Miami, with
offices in Dallas, Shanghai and Tokyo.
Follow us on Facebook [ https://www.facebook.com/INSIGHTEC.MRgFUS/ ], LinkedIn
[ https://www.linkedin.com/company/insightec/ ]and Twitter [
https://twitter.com/INSIGHTEC ]or visit www.insightec.com for more information.
Forward-looking Statements
This document contains forward-looking statements regarding, among other
things, plans, expectations, and future events. In some cases, forward-looking
statements can be identified by the following words: "may," "can," "will,"
"could," "would," "should," "expect," "intend," "plan," "anticipate,"
"believe," "estimate," "predict," "project," "potential," "promise,"
"continue," "ongoing," or the negative of these terms. Forward-looking
statements involve known and unknown risks, uncertainties and other important
factors that could cause actual results to differ materially from what is
expressed or implied by the statements. Any forward-looking statement is based
on information available to Insightec as of the date of the statement. All
written or oral forward-looking statements attributable to Insightec are
qualified by this caution. Insightec does not undertake any obligation to
update or revise any forward-looking statement to reflect any change in
circumstances or in Insightec's expectations.
"Exablate," and "Exablate Neuro," as well as the "INSIGHTEC" logo, whether
standing alone or in connection with the word " Insightec", are protected
trademarks of Insightec.
Insightec Media Contact
G&S Business Communications for Insightec
Elizabeth Mannheimer
+1 917.595.3034
emannheimer@gscommunications.com
Logo - https://mma.prnewswire.com/media/1120780/Insightec_Logo.jpg
Source: Insightec
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。